Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

Nat Commun. 2019 Nov 15;10(1):5257. doi: 10.1038/s41467-019-13151-z.

¹ Medical Scientist Training Program, Oregon Health & Science University, Portland, OR, USA.
² Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.
³ Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA.
⁴ Department of Computational Biology, Oregon Health & Science University, Portland, OR, USA.
⁵ Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
⁶ Departments of Medicine and Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.
⁷ Department of Pathology, Oregon Health & Science University, Portland, OR, USA.
⁸ Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA. marksd@ohsu.edu.
⁹ Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR, USA. marksd@ohsu.edu.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.